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HONEST Study: Morning Home Blood Pressure 
(BP) May be Superior to Clinic BP as a Predictor of 
Coronary Events and Stroke in Patients With 
Hypertension  
In 21,591 hypertensive patients (mean age ~65 years), 
having 127 stroke and 121 CAD events over a mean 
follow-up of 2 years, the incidence of stroke events was 
significantly higher in patients with morning home systolic 
blood pressure (HSBP) ≥145 mmHg compared with <125 
mmHg (hazard ratio -HR ~6.0), and in patients with clinic 
systolic blood pressure (CSBP) ≥150 mmHg compared 
with <130 mmHg (HR 5.82); morning HSBP predicted 
stroke events similarly to CSBP. Incidence of CAD events 
was significantly higher in patients with morning HSBP 
≥145 mmHg compared with <125 mmHg (HR 6.24) and 
in patients with CSBP ≥160 mmHg compared with <130 
mmHg (HR 3.51). Thus, compared with morning HSBP 
predicted CAD events more strongly than CSBP (Kario K 
et al, J Am Coll Cardiol 2016;67:1519-1527).  
A 1-h Combination Algorithm Allows Fast Rule-Out/ 
Rule-In of Major Adverse Cardiac Events (MACE): In 
Patients with Chest Pain Presenting to Emergency 
Department (ED), Combining hs-cTnT Levels on 
Arrival and 1 h Later With the Patient History and 
ECG More Effectively Identified MACE Within 30 
Days Than Screening Based on hs-cTnT Alone  
In a prospective observational study enrolling 1,038 
patients presenting to the emergency department (ED) with 
chest pain, an extended algorithm comprising hs-cTnT 
results at 1 h combined with history and ECG, identified 
60% of all patients for rule-out and had a higher sensitivity 
than the troponin algorithm alone (97.5% vs 87.6%; p< 
0.001). The negative predictive value was 99.5% and the 
likelihood ratio was 0.04 with the extended algorithm vs 
97.8% and 0.17, respectively, with the troponin algorithm. 
The extended algorithm ruled-in 14% of patients with a 
higher sensitivity (75.2% vs 56.2%; p< 0.001) but a 
slightly lower specificity (94.0% vs 96.4%; p< 0.001) than 
the troponin algorithm. The rule-in arms of both 
algorithms had a likelihood ratio >10 (Mokhtari A et al, J 
Am Coll Cardiol 2016;67:1531-1540).  
CTSN Trial: Strategies for Rate and Rhythm Control 
to Treat Postoperative Atrial Fibrillation (AF): Neither 
Treatment Strategy Showed a Net Clinical Advantage 
Over the Other / They were Associated With Equal 
Numbers of Days of Hospitalization, Similar 
Complication Rates, and Similarly Low Rates of 
Persistent AF 60 Days After Onset   
Among 695 of 2109 patients (33%) who had AF after 
cardiac surgery, 523 underwent randomization to heart-
rate or rhythm control. The total numbers of hospital days 
were similar in the 2 groups (median, 5.1 and 5 days, 
respectively; P = NS). There were no significant between-
group differences in the rates of death (P = NS) or overall 
serious adverse events (24.8 per 100 patient-months in the 
rate-control group and 26.4 per 100 patient-months in the 
rhythm-control group, P = NS), including thromboembolic 
and bleeding events. About 25% of patients in each group 
deviated from the assigned therapy, mainly because of 
drug ineffectiveness (in the rate-control group) or 
amiodarone side effects or adverse drug reactions (in the 
rhythm-control group). At 60 days, 93.8% of the patients 
in the rate-control group and 97.9% of those in the rhythm-
control group had had a stable heart rhythm without AF for 
the previous 30 days (P = 0.02), and 84.2% and 86.9%, 
respectively, had been free from AF from discharge to 60 
days (P = NS) (Gillinov AM et al, N Engl J Med 2016; 
374:1911-1921).   
COGENT: Gastroprotection With Proton Pump 
Inhibitors (PPIs) Should be Utilized in Appropriately 
Selected Patients With Coronary Artery Disease 
Requiring Dual Antiplatelet Therapy (DAPT), Even if 
Patients are on Low-Dose Aspirin  
High-dose aspirin users (n= 1,272 or 34%; higher rates 
of hyperlipidemia, smoking and history of PCI) had similar 
6-month Kaplan-Meier estimates of adjudicated composite 
gastrointestinal (GI) events (1.7% vs 2.1%; hazard ratio - 
HR: 0.88) and major adverse cardiac events (4.8% vs 
5.5%; HR: 0.73) compared with low-dose aspirin users (n= 
2,480 or 66%; older, female, and with higher rates of 
peripheral artery disease, prior stroke, and hypertension). 
Randomization to PPI therapy reduced 6-month Kaplan-
Meier estimates of the primary GI endpoint in low-dose 
(1.2% vs 3.1%) and high-dose aspirin subsets (0.9% vs 
2.6%), and did not adversely affect the primary 
cardiovascular endpoint in either group (Vaduganathan M 
et al, J Am Coll Cardiol 2016;67:1661-1671).   
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Left Ventricular Assist Device (VAD) May Improve 
Clinical Outcomes of Patients With Acute Myocardial 
Infarction (AMI) and Heart Failure Who do not 
Respond Adequately to Conventional Therapy  
VAD were implanted in 502 patients with AMI and 
66% were INTERMACS profile 1 in 66% (median age 
58.3 years, 77% male): 443 left VADs; 33 bi-VADs; and 
26 total artificial hearts. A higher proportion of AMI than 
non-AMI patients had pre-operative intra-aortic balloon 
pumps (57.6% vs 25.3%; p< 0.01), intubation (58% vs 
8.3%; p< 0.01), extracorporeal membrane oxygenation 
(17.9% vs 1.7%, p< 0.01), cardiac arrest (33.5% vs 3.3%, 
p< 0.01), and higher-acuity INTERMACS profiles. At 1 
month post-VAD, 91.8% of AMI patients were alive with 
ongoing device support, 7.2% had died on device, and 1% 
had been transplanted. At 1-year post-VAD, 52% of AMI 
patients were alive with ongoing device support, 25.7% 
had been transplanted, 1.6% had left VAD explanted for 
recovery, and 20.7% had died on device. The AMI group 
had higher early phase hazard (hazard ratio - HR: 1.24; p= 
0.04) and reduced late-phase hazard of death (HR: 0.57; p= 
0.04) than the non-AMI group did. After accounting for 
established risk factors, the AMI group no longer had 
higher early mortality hazard (HR: 0.89; p= 0.30), but it 
had lower late mortality hazard (HR: 0.55; p= 0.02) 
(Acharya D et al, J Am Coll Cardiol 2016;67:1871-1880).   
ALBATROSS Trial: A Mineralocorticoid Receptor 
Antagonist (MRA) Given Early After Myocardial 
Infarction (MI) did not Reduce the Composite of 
Death, Ventricular Arrhythmia, Cardiac Arrest, Need 
for Implantable Defibrillator, or New or Worsening 
Heart Failure (HF) at 6 Months, but Seemed to Lower 
Mortality Among Those Presenting With ST-Segment 
Elevation MI (STEMI) 
Among 1,603 patients presenting with acute MI (92% of 
whom presented without HF) and randomized to receive 
an MRA regimen with a single intravenous bolus of 
potassium canrenoate (200 mg) followed by oral 
spironolactone (25 mg once daily) for 6 months in addition 
to standard therapy or standard therapy alone, the primary 
outcome occurred in 95 (11.8%) and 98 (12.2%) patients 
in the treatment and control groups, respectively (hazard 
ratio - HR: 0.97). Death occurred in 11 (1.4%) and 17 
(2.1%) patients in the treatment and control groups, 
respectively (HR: 0.65). The odds of death were reduced 
in the treatment group (3 or 0.5% vs 15 or 2.4%; HR: 0.20) 
in the subgroup of STEMI (n = 1,229), but not in non–
STEMI (p for interaction = 0.01). Hyperkalemia >5.5 
mmol/l–1 occurred in 3% and 0.2% of patients in the 
treatment and standard therapy groups, respectively (p < 
0.0001) (Beygui F et al, J Am Coll Cardiol 2016;67:1917-
1927).   
Takotsubo (TS) Registry: Patients Predisposed To TS 
Stress Cardiomyopathy Typically Have a Low 
Cardiovascular Risk Profile But Increased COPD, 
Migraine and Affective Disorders. Risk is Increased in 
Those Using Β2-Adrenergic Agonist Agents and 
Medications for Migraine / Mortality Rate is Similar to 
Patients With Acute Coronary Syndromes  
Of the 505 patients with TS cardiomyopathy (TSC), 
442 (87.5%) were women (mean age of 67 ± 10 years). The 
largest age group was between 60 and 69 years old with 
one-fifth of the patients <60 years of age. Compared with 
CAD control subjects (n= 1,010), patients with TSC were 
characterized by a low cardiovascular risk factor profile 
but with increased chronic obstructive pulmonary disease 
(COPD), migraine, and affective disorders. The use of 
beta-blockers was less common but use of β2-adrenergic 
agonist agents was more common in patients with TSC 
compared with either of the control groups. Being a patient 
with TSC was associated with a hazard ratio of 2.1 for 
death compared with the control subjects without CAD (n= 
1,007). This was similar to the excess mortality risk seen 
among the CAD control subjects compared with control 
subjects without CAD (hazard ratio: 2.5) (Tornvall P et al, 
J Am Coll Cardiol 2016;67:1931-1936).   
UK Registry: Causes of Sudden Cardiac Death (SCD) 
in Athletes Vary With Age. Sudden Arrhythmic Death 
Syndrome (SADS) is Prevalent in Children and 
Adolescents, Whereas Cardiomyopathies are the Most 
Common Cause in Adults. Arrhythmogenic Right 
Ventricular Cardiomyopathy (ARVC) is Strongly 
Associated With SCD During Exertion  
Autopsies were performed in 357 consecutive cases of 
athletes who died suddenly (mean 29 ± 11 years of age, 
92% males, 76% Caucasian, 69% competitive). Sudden 
arrhythmic death syndrome (SADS) was the most 
prevalent cause of death (n= 149 or 42%), mostly in young 
athletes. This was a diagnosis of exclusion, defined as a 
structurally normal heart with no evident abnormality on 
macroscopic and histological evaluation and a negative 
result for toxicology screening, underscoring the 
importance of inherited primary arrhythmia syndromes as 
a major cause of SCD in athletes. Myocardial disease was 
detected in 40% of cases (mostly older athletes), including 
idiopathic left ventricular hypertrophy (LVH) and/or 
fibrosis (n= 59, 16%); ARVC (13%); and hypertrophic 
cardiomyopathy (HCM) (6%). Coronary artery anomalies 
occurred in 5% of (mostly young) cases. SCD during 
intense exertion occurred in 61% of cases (particularly in 
ARVC and left ventricular fibrosis). Almost 40% of 
athletes die at rest, highlighting the need for 
complementary preventive strategies (Finocchiaro G et al, 
J Am Coll Cardiol 2016;67:2108-2115).  
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BLOCK HF Trial: In Patients With AV Block (AVB) 
& Heart Failure, Biventricular Compared With RV 
Pacing is Associated With Improvement in Survival, 
Heart Failure-Related Urgent Care, and Adverse 
Ventricular Remodeling, Better Functional Capacity 
and Quality of Life  
Among 691 patients with AVB, NYHA symptom class 
I to III heart failure, and left ventricular ejection 
fraction≤50% randomized to biventricular (n=349) or right 
ventricular (RV) pacing (n=342), biventricular pacing 
conferred greater improvement in NYHA class at 12 
months, with 19% improved, 61% unchanged, and 17% 
worsened, compared with 12%/62%/ 23% in the RV arm. 
QOL was improved through 12 months. At 6 months, 
clinical composite score was improved/unchanged/ 
worsened in 53%/24%/24% in the biventricular arm 
compared with 39%/33%/28% in the RV arm. This 
improvement was sustained through 24 months (Curtis AB 
et al, J Am Coll Cardiol 2016;67:2148-2157).   
OBSERVANT Study: In Patients With Low Operative 
Risk, Significantly Better 3-Year Survival and 
Freedom From Major Adverse Cardiac And Cerebro-
vascular Events (MACCE) were Observed after 
Surgical Aortic Valve Replacement (SAVR) Compared 
With Transcatheter Aortic Valve Implantation (TAVI)  
One month survival was 97.1% after SAVR and 97.4% 
after TAVI (P=NS) among 355 low-risk patients in each 
group (EuroSCORE II <4%). Cardiac tamponade, 
pacemaker implantation, major vascular damage, and 
moderate-to-severe paravalvular regurgitation were 
significantly more frequent after TAVI compared with 
SAVR. Stroke rates were equal. SAVR was associated 
with higher risk of cardiogenic shock, severe bleeding, and 
acute kidney injury. At 3 years, survival was 83.4% after 
SAVR and 72% after TAVI (P=0.0015), and freedom from 
MACCE was 80.9% after SAVR and 67.3% after TAVI 
(P<0.001) (Rosato S et al, Circ Cardiovasc Interv 
2016;9:e003326).  
PARTNER II: In Intermediate-Risk Patients, TAVI 
was Similar to Surgical Aortic-Valve Replacement 
(AVR) With Respect to Death or Disabling Stroke 
Among 2032 intermediate-risk (STS risk score of >4% 
& <8%) patients with severe aortic stenosis, randomly 
assigned to TAVI or surgical AVR, the rate of death from 
any cause or disabling stroke was similar (P=0.001 for 
noninferiority). At 2 years, the Kaplan–Meier event rates 
were 19.3% in the TAVI and 21.1% in the surgery group 
(hazard ratio – HR in TAVI, 0.89; P=NS). In the trans-
femoral-access cohort, TAVI resulted in a lower rate of 
death or disabling stroke than surgery (HR, 0.79; P=0.05), 
whereas in the transthoracic-access cohort, outcomes were 
similar in the two groups. TAVI resulted in larger aortic-
valve areas and also in lower rates of acute kidney injury, 
severe bleeding, and new-onset atrial fibrillation; surgery 
resulted in fewer major vascular complications and less 
paravalvular aortic regurgitation (Leon MB et al, N Engl J 
Med 2016; 374:1609-1620).  
Propensity Score Analysis: TAVI With SAPIEN 3 in 
Intermediate-Risk Severe Aortic Stenosis Patients is 
Confers Low Mortality, Strokes, & Regurgitation at 1 
Year & Appears Superior to Surgery 
At 1 year follow-up of the SAPIEN 3 observational 
study, 79 of 1077 intermediate-risk patients had died (all-
cause mortality 7·4%; 6·5% in the transfemoral access 
subgroup), and disabling strokes had occurred in 24 (2%), 
aortic valve re-intervention in 6 (1%), and moderate or 
severe paravalvular regurgitation in 13 (2%). In the 
propensity-score analysis comprising 963 TAVI patients 
receiving SAPIEN 3 and 747 with surgical valve 
replacement (PARTNER 2A trial), for the primary 
composite endpoint of mortality, strokes, and moderate or 
severe aortic regurgitation, TAVI was both non-inferior 
(pooled weighted proportion difference of −9·2%; 
p<0.0001) and superior (−9·2%; p<0.0001) to surgical 
valve replacement (Thourani VH et al, Lancet 2016; 387 
(10034):2218–2225).   
A Case–Control Study: Deficiency of the Aortic or any 
Rim, Device >5 mm Larger than ASD Diameter, and 
Weight: Device Size Ratio are Risk Factors for Cardiac 
Erosion Following Transcatheter Closure of Atrial 
Septal Defects (ASDs) 
Among 125 erosions reported after ASD closure with 
an Amplatzer septal occlude, the median duration from 
implant to erosion was 14 days, but was >1 year in 16 
patients. Nine patients (aged ≥17 years) who died were 
more likely to have an oversized device, and to have 
erosion into the aorta, than survivors. Aortic or superior 
vena cava rim deficiencies were more common in cases 
than in controls. In addition, larger balloon-sized ASD 
diameter, Amplatzer septal occluder device size, and 
device size–ASD diameter difference, and smaller weight-
to-device size ratio were associated with erosion. On 
multivariable analysis, deficiency of any rim, device >5 
mm larger than ASD diameter, and weight:device size 
ratio were associated with erosion (McElhinney DB et al, 
Circulation 2016; 133:1738-1746.   
The ABC (Age, Biomarkers, Clinical History) Stroke 
Risk Score: A Better Biomarker-Based Risk Score for 
Predicting Stroke in Atrial Fibrillation? 
A new risk score, the ABC (Age, Biomarkers, Clinical 
history) score, was developed and validated in 14,701 AF 
patients, with further external validation in another 1400 
AF patients. The most important predictors were prior 
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stroke/transient ischemic attack, NT-proBNP, cTn-hs, and 
age. The ABC-stroke score was well calibrated and yielded 
higher c-indices than the widely used CHA2DS2-VASc 
score in both the derivation cohort (0.68 vs. 0.62, P < 
0.001) and the external validation cohort (0.66 vs. 0.58, P 
< 0.001) (Hijazi Z et al, Eur Heart J 2016; 37:1582-1590).  
ARISTOTLE /RE-LY Investigators: ABC-Bleeding 
Score, Using Age, Bleeding History, & 3 Biomarkers 
(Hemoglobin, cTn-hs, and GDF-15 or Cystatin 
C/CKD-EPI) Performed Better than HAS-BLED & 
ORBIT Scores in Patients with Atrial Fibrillation (AF) 
The ABC-bleeding score (age, biomarkers [growth 
differentiation factor-15 or GDF-15, high-sensitivity 
cardiac troponin T or cTnT-hs, and hemoglobin], and 
clinical history of previous bleeding) yielded a higher c-
index than HAS-BLED and ORBIT scores for major 
bleeding in both the derivation (n=14,537, ARISTOTLE 
trial) cohort (0.68 vs 0.61 vs 0.65, respectively; ABC-
bleeding vs HAS-BLED p<0.0001 and ABC-bleeding vs 
ORBIT p=0.0008), and in the external validation (n=8468, 
RE-LY trial) cohort (0.71 vs 0.62 for HAS-BLED vs 0.68 
for ORBIT; ABC-bleeding vs HAS-BLED p<0.0001 and 
ABC-bleeding vs ORBIT p=0.0016). A modified ABC-
bleeding score using alternative biomarkers (hematocrit, 
cTnI-hs, cystatin C, or creatinine clearance) also 
outperformed the HAS-BLED and ORBIT scores (Hijazi 
Z et al, Lancet 2016; 387 (10035): 2302–2311).   
ACC PINNACLE Registry: High Undertreatment 
Rate (38-40%) With Aspirin Alone Instead of Oral 
Anticoagulant (OAC) in Atrial Fibrillation Patients at 
Risk for Stroke, Usually Associated With Conditions 
Related to Coronary Disease (CAD) 
Among 210,380 AF patients with CHADS2 score ≥2, 
80,371 (38.2%) were treated with aspirin alone, and 
130,009 (61.8%) with warfarin or non-vitamin K 
antagonist OACs. In another cohort of 294,642 patients 
with CHA2DS2-VASc ≥2, 118,398 (40.2%) were treated 
with aspirin alone, and 176,244 (59.8%) with warfarin or 
non-vitamin K antagonist OACs. After multivariable 
adjustment, hypertension, dyslipidemia, CAD, prior MI, 
unstable and stable angina, recent CABG, and peripheral 
arterial disease were associated with prescription of aspirin 
only, whereas male gender, higher body mass index, prior 
stroke/TIA, prior systemic embolism, and congestive heart 
failure were associated with more frequent prescription of 
OAC (Hsu J et al; J Am Coll Cardiol 2016; 67:2913-2923).   
Non-Paroxysmal (NPAF) Compared to Paroxysmal 
Atrial Fibrillation (PAF) is Associated With a Highly 
Significant Increase in Thromboembolism and Death  
According to 12 studies comprising 99,996 patients, the 
unadjusted risk ratio (RR) for thromboembolism in NPAF 
vs PAF was 1.355 (P< 0.001). In the study subset off oral 
anticoagulation, unadjusted RR was 1.689 (P= 0.007). The 
overall multivariable adjusted hazard ratio (HR) for 
thromboembolism was 1.384 (P< 0.001). The overall 
unadjusted RR for all-cause mortality was 1.462 (P< 
0.001)and the adjusted HR for all-cause mortality was 
1.217 (P< 0.001). Rates of bleeding were similar (Ganesan 
AN et al, Eur Heart J 2016;37:1591-1602).   
VINDICATE Study: In Patients With Chronic Heart 
Failure (HF), Vitamin D Deficiency is Common, and 
High-Dose Vitamin D3 Supplementation is Safe, Well 
Tolerated, and Associated With a Favorable Effect on 
Cardiac Function   
Among 229 patients (179 men) with chronic HF and 
vitamin D deficiency (cholecalciferol<50 nmol/l or <20 
ng/ml), randomized to 1 year of vitamin D3 (4,000 IU or 
100 μg daily) or matching non−calcium-based placebo, the 
6-min walk distance at 1 year did not improve, but there 
was a significant improvement in cardiac function 
(ejection fraction +6.07%; p< 0.0001); and a reversal of 
LV remodeling (LV end diastolic diameter -2.49 mm and 
LV end systolic diameter -2.09 mm (p= 0.043) (Witte KK 
et al, J Am Coll Cardiol 2016;67:2593-2603.).  
Percutaneous Mitral Valve Plication With the Mitral 
Clip May be Effective for Symptom Relief in Patients 
With Obstructive Hypertrophic Cardiomyopathy 
(HCM) via Reduction of Systolic Anterior Motion 
(SAM) and Mitral Regurgitation (MR)  
Percutaneous mitral valve leaflet plication to reduce 
SAM and MR using the transcatheter mitral clip system 
was completed in 5 of 6 referred patients (age 83 ± 8 years; 
5 women) (one patient had cardiac tamponade and the 
procedure was aborted). SAM was eliminated and the 
intraoperative LVOT gradient (91 ± 44 mmHg to 12 ± 6 
mmHg; p= 0.007), left atrial pressure (29 ± 11 mmHg to 
20 ± 8 mmHg; p= 0.06), and MR grade (3.0 ± 0 vs. 0.8 ± 
0.4; p= 0.0002) were decreased, associated with improved 
cardiac output (in n= 4; 3.0 ± 0.6 l/min to 4.3 ± 1.2 l/min; 
p= 0.03). Over 15 ± 4 months, symptom improvement to 
NYHA class I or II occurred in all patients. Follow-up 
echocardiography demonstrated continued absence of 
SAM and significant reduction in MR, although high 
systolic LVOT velocities (i.e., >4 m/s) were evident in 3 
of the 5 treated patients (Sorajja P et al, J Am Coll Cardiol 
2016;67:2811-2818).   
EARLY-BAMI Trial: In Patients With Acute STEMI 
Given IV Metoprolol within 12 h Before Primary 
Angioplasty, Infarct Size Measured by CMR was not 
Significantly Different Than in Those Given a Placebo 
A total of 683 STEMI patients (mean age 62 ± 12 years; 
75% male) presenting within 12 h were randomized to IV 
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metoprolol (n= 336) or placebo (n= 346). Infarct size by 
cardiac magnetic resonance (CMR) (performed in 342 
patients) did not differ between the metoprolol (15.3 ± 
11%) and placebo groups (14.9 ± 11.5%; p= 0.616). Peak 
and area under the creatine kinase curve did not differ 
between groups. LV ejection fraction by CMR did not 
differ. Incidence of malignant arrhythmias was 3.6% in the 
metoprolol group vs 6.9% in placebo (p= 0.050). Incidence 
of adverse events was not different between groups 
(Roolvink V et al, J Am Coll Cardiol 2016; 67:2705-2715).  
Trimethylamine N-oxide (TMAO), an Intestinal 
Microbe-Generated Phosphatidylcholine Metabolite is 
Related to the Pathogenesis of Atherosclerotic CAD  
TMAO arises from gut microbiota metabolism 
following ingestion of diets rich in phosphatidylcholine (or 
lecithin), the major dietary source of choline, and carnitine, 
an abundant nutrient in red meat. In 353 consecutive stable 
patients with angiographic evidence of CAD, the median 
TMAO level was 5.5 μM, the median SYNTAX score was 
11, and 289 (81.9%), 40 (11.3%), and 24 (6.8%) patients 
had low (0 to 22), intermediate (23 to 32), and high (≥33) 
SYNTAX scores, respectively. Plasma TMAO levels 
correlated (all p<0.0001) with the SYNTAX score (r= 
0.61), SYNTAX score II (r= 0.62), and hs-cTnT (r= 0.29). 
After adjustment, elevated TMAO levels remained 
independently associated with a higher SYNTAX score 
(odds ratio - OR: 4.82; p< 0.0001), SYNTAX score II (OR: 
1.88; p= 0.0001), but were not associated with subclinical 
myonecrosis (OR: 1.14; p= 0.3147). Elevated TMAO level 
was an independent predictor of the presence of diffuse 
lesions, even after adjustments for traditional risk factors 
and for hs-cTnT (OR: 2.05; p= 0.0001) (Senthong V et al, 
J Am Coll Cardiol 2016;67:2620-2628).  
The Stepathlon Cardiovascular Health Study: Light 
Weight, Low-Cost, Noninteractive Pedometers Can 
Promote Modest Improvements in Physical Activity, 
Sitting, and Weight Among Private and Public Sector 
Employees  
Stepathlon, a low-cost, pedometer-based, workplace 
physical activity and wellness program, which utilized an 
mHealth technology-based approach to facilitate large-
scale implementation and program delivery, was 
conducted annually as a 100-day event, aiming to 
encourage participants to increase step counts and physical 
activity. After Stepathlon completion, participants 
(N=69,219, age 36 ± 9 years, 23.9% female, 92% lower-
middle income countries) recorded improved step count 
(+3,519 steps/day; p< 0.0001), exercise days (+0.89 days; 
p < 0.0001), sitting duration (−0.74 h; p< 0.0001) and 
weight (−1.45 kg; p< 0.0001). Improvements occurred in 
women and men, in all geographic regions, and in both 
high and lower-middle income countries, with 
reproducible annual results. Predictors of weight loss 
included step increase, sitting duration decrease, and 
increase in exercise days (all p< 0.0001) (Ganesan AN et 
al, J Am Coll Cardiol 2016; 67:2453-2463).   
A Study of 1.5 Million Blood Donors: Non-O Blood 
Groups Explain >30% of Venous Thromboembolic 
Events  
in Denmark and Sweden (1987-2012), a total of 9170 
venous and 24,653 arterial thromboembolic events 
occurred in 1,112,072 blood donors; compared with blood 
group O, non-O blood groups were associated with higher 
incidence of both venous and arterial events. The highest 
rate ratios (RR) were observed for pregnancy-related 
venous thromboembolism (RR, 2.22), deep vein 
thrombosis (RR, 1.92), and pulmonary embolism (RR, 
1.80) (Vasan SK et al, Circulation 2016;133:1449-1457).   
CMR Study in Male Elite Master Athletes: the 
Hypothesis of an Exercise-Induced Arrhythmogenic 
Right Ventricular (RV) Cardiomyopathy is Questioned 
Among 33 healthy white competitive elite male master 
endurance athletes (age 30–60 years) with a training 
history of 29±8 years, and 33 pair-matched white controls, 
undergoing cardiopulmonary exercise testing, Doppler and 
speckle tracking echocardiography, and cardiovascular 
magnetic resonance (CMR), indexed left ventricular (LV) 
(96±13 and 62±10 g/m2; P<0.001), and RV mass (36±7 
and 24±5 g/m2; P<0.001) and indexed LV (104±13 and 
69±18 mL/m2; P<0.001) and RV end-diastolic volume 
(110±22 and 66±16 mL/m2; P<0.001) were significantly 
increased in athletes in comparison with control subjects. 
RV ejection fraction did not differ between athletes and 
controls (52±8 and 54±6%; P=NS). Pathological late 
enhancement was detected in 1 athlete. No correlations 
were found for LV and RV volumes and ejection fraction 
with NT-proBNP, and high-sensitive troponin was 
negative in all subjects (Bohm P et al, Circulation 
2016;133:1927-1935).   
STICHES Trial: Coronary Artery Bypass (CABG) 
Improves Survival in Ischemic Cardiomyopathy 
Among 1212 coronary artery disease patients with an 
ejection fraction of <35%, randomly assigned to CABG 
plus medical therapy (CABG group, n=610) or medical 
therapy alone (medical-therapy group, n=602), over 9.8 
years, death occurred in 359 patients (58.9%) in the CABG 
group and in 398 patients (66.1%) in the medical group 
(hazard ratio – HR with CABG vs medical therapy, 0.84; 
P=0.02). A total of 247 patients (40.5%) in the CABG 
group and 297 patients (49.3%) in the medical-therapy 
group died from cardiovascular causes (HR, 0.79; 
P=0.006). Death from any cause or hospitalization for 
cardiovascular causes occurred in 467 patients (76.6%) in 
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the CABG and in 524 patients (87.0%) in the medical 
group (HR, 0.72; P<0.001) (Velazquez EJ et al, N Engl J 
Med 2016; 374:1511-1520).   
Resuscitation Outcomes Consortium (ROC): In Out-
Of-Hospital Cardiac Arrest (OOHCA) Due to Shock-
Refractory VF or Pulseless VT, Neither Amiodarone 
Nor Lidocaine Resulted in a Higher Rate of Survival or 
Favorable Neurologic Outcome Than Placebo  
Among 3026 OOHCA patients, randomly assigned to 
amiodarone (974), lidocaine (993), or placebo (1059), 
24.4%, 23.7%, and 21%, respectively, survived to hospital 
discharge. The difference in survival rate for amiodarone 
vs placebo was 3.2% (P=0.08); for lidocaine vs placebo, 
2.6%; and for amiodarone vs lidocaine, 0.7% (P=0.70). 
Neurologic outcome at discharge was similar in the 3 
groups. There was heterogeneity of treatment effect with 
respect to whether the arrest was witnessed (P=0.05); both 
drugs were associated with a higher survival rate than 
placebo among patients with bystander-witnessed arrest 
but not among those with unwitnessed arrest. More 
amiodarone recipients required temporary cardiac pacing 
(Kudenchuk PJ et al, N Engl J Med 2016; 374:1711-1722).  
HOPE-3 Trials: Among Persons at Intermediate Risk 
With no Cardiovascular Disease, Antihypertensive 
Therapy With Candesartan plus Diuretic Does not 
Protect from Major Cardiovascular Events, but 
Therapy With Rosuvastatin or Combined Rosuvastatin 
and Candesartan plus Hydrochlorothiazide Does 
Among 12,705 participants at intermediate risk with no 
cardiovascular disease (mean baseline blood pressure 
138.1/81.9 mm Hg) randomly assigned to candesartan (16 
mg/d) plus hydrochlorothiazide (12.5 mg/d) or placebo, 
over a median follow-up of 5.6 years, the decrease in blood 
pressure was 6/3 mm Hg greater in the active-treatment 
group. The first coprimary outcome (composite of 
cardiovascular death, nonfatal MI, or stroke) occurred in 
260 participants (4.1%) with active-treatment and in 279 
(4.4%) with placebo (hazard ratio-HR, 0.93; P=NS); the 
second coprimary outcome (heart failure, cardiac arrest, or 
revascularization) occurred in 312 participants (4.9%) and 
328 participants (5.2%), respectively (HR, 0.95; P=NS) 
(Lonn EM et al, N Engl J Med 2016; 374:2009-2020).  
In the same cohort, random assignment to rosuvastatin 
(10 mg/d) or placebo led to 26.5% lower LDL cholesterol 
in the active treatment group. The first coprimary outcome 
occurred in 235 participants (3.7%) in the rosuvastatin 
group and in 304 participants (4.8%) in the placebo group 
(HR, 0.76; P=0.002). The results for the second coprimary 
outcome were consistent with the results for the first 
(occurring in 277 participants or 4.4% in the rosuvastatin 
group and in 363 participants or 5.7% in the placebo group; 
HR, 0.75; P<0.001). In the rosuvastatin group, there was 
no excess of diabetes or cancers, but there was an excess 
of cataract surgery (3.8% vs 3.1%; P=0.02) and muscle 
symptoms (5.8% vs 4.7%; P=0.005) (Yusuf S et al, N Engl 
J Med 2016; 374:2021-2031).  
Finally, among those (n=3180) assigned to combined 
therapy (rosuvastatin and the 2 antihypertensive agents) 
compared with the 3168 assigned to dual placebo, the first 
coprimary outcome occurred in 113 participants (3.6%) in 
the combined-therapy group and in 157 (5%) in the dual-
placebo group (HR, 0.71; P=0.005). The second coprimary 
outcome occurred in 136 participants (4.3%) and 187 
participants (5.9%), respectively (HR, 0.72; P=0.003). 
Muscle weakness and dizziness were more common in the 
combined-therapy than in the dual-placebo group, but the 
overall discontinuation rate was similar in the two groups 
(Yusuf S et al, N Engl J Med 2016; 374:2032-2043).   
FIRE AND ICE: Cryoballoon Ablation Noninferior to 
Radiofrequency Ablation With Respect to Efficacy and 
Safety in Patients With Drug-Refractory Paroxysmal 
Atrial Fibrillation (PAF) 
Among 762 PAF patients randomized to cryoballoon 
(n=378) or radiofrequency ablation (n=384), over mean 
follow-up of 1.5 years, the primary efficacy end point (first 
documented clinical failure, i.e. recurrence of AF, 
occurrence of atrial flutter or atrial tachycardia, use of 
antiarrhythmic drugs, or repeat ablation following a 90-day 
period after the index ablation, occurred in 138 patients in 
the cryoballoon group and in 143 in the radiofrequency 
group (1-year event rates, 34.6% and 35.9%, respectively; 
hazard ratio-HR, 0.96; P<0.001 for noninferiority). The 
primary safety end point (composite of death, 
cerebrovascular events, or serious treatment-related 
adverse events) occurred in 40 patients in the cryoballoon 
group and in 51 patients in the radiofrequency group (1-
year event rates, 10.2% and 12.8%, respectively; hazard 
ratio, 0.78; P=NS) (Kuck K_H et al, N Engl J Med 2016; 
374:2235-2245).   
HERMES Collaboration Meta-Analysis of 5 
Randomized Trials: Endovascular Thrombectomy 
After Large-Vessel Ischemic Stroke is of Benefit to 
Most Patients / Timely Treatment should be Provided 
to These Patients  
In 2015, 5 randomized trials showed efficacy of 
endovascular thrombectomy over medical care in patients 
with acute ischemic stroke caused by occlusion of 
proximal anterior cerebral arteries. Patient data for 1287 
patients (634 assigned to endovascular thrombectomy, 653 
assigned to control), pooled from these trials (MR 
CLEAN, ESCAPE, REVASCAT, SWIFT PRIME, and 
EXTEND IA), indicated that endovascular thrombectomy 
led to significantly reduced disability at 90 days compared 
with control (adjusted common odds ratio-cOR 2·49; 
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p<0.0001). The number needed to treat with endovascular 
thrombectomy to reduce disability by at least one level on 
modified Rankin scale-mRS for one patient was 2.6. Effect 
sizes favouring endovascular thrombectomy over control 
were present in several strata of special interest, including 
in patients aged >80 years (cOR 3.68), those randomized 
>5h after symptom onset (cOR 1.76), and those not eligible 
for intravenous alteplase (2.43). Mortality at 90 days and 
risk of parenchymal hematoma and symptomatic 
intracranial hemorrhage did not differ between populations 
(Goyal M et al, Lancet 2016; 387 (10029):1723–1731).   
DANAMI 3-DEFER: No advantage of Deferred Stent 
Implantation vs Standard PCI in Patients With ST-
Segment Elevation Myocardial Infarction (STEMI) 
Among 1215 patients with STEMI randomized to 
primary PCI with immediate stent implantation (n=612) or 
deferred stent implantation 48 h after the index procedure 
if a stabilized flow could be obtained in the infarct-related 
artery (n=603), at a median follow-up of 42 months, the 
primary endpoint (all-cause mortality, hospital admission 
for heart failure, recurrent infarction, and any unplanned 
revascularization of the target vessel) occurred in 109 
(18%) patients who had standard PCI and in 105 (17%) 
patients who had deferred stent implantation (hazard ratio 
0·99; p=NS). Procedure-related MI, bleeding requiring 
transfusion or surgery, contrast-induced nephropathy, or 
stroke occurred in 28 (5%) vs 27 (4%) patients, with no 
significant differences between groups (Kelbæk H et al, 
Lancet 2016; 387 (10034):2199–2206).   
ixCELL-DCM: Transendocardial Delivery of Cellular 
Therapy with Ixmyelocel-T in Patients With Reduced-
Ejection Fraction Ischemic Heart Failure Resulted in 
Significant Reduction in Cardiac Events Compared 
With Placebo Leading to Improved Patient Outcomes  
Ixmyelocel-T is an expanded, multicellular therapy 
produced from a patient's own bone marrow by selectively 
expanding two key types of bone marrow mononuclear 
cells: CD90+ mesenchymal stem cells and CD45+ CD14+ 
auto-fluorescent+ activated macrophages. Randomized 
catheter-based transendocardial injection of ixmyelocel-T 
cell therapy in 66 patients with heart failure and reduced 
ejection fraction compared with placebo (n=60) led to 
primary efficacy endpoint (all-cause death, cardiovascular 
admission, and unplanned clinic visits to treat acute heart 
failure) being observed in 47 patients: 50 events in 25 
(49%) of 51 patients in the placebo group and 38 events in 
22 (38%) of 58 patients in the ixmyelocel-T group, which 
represents a 37% reduction in cardiac events compared 
with placebo (risk ratio 0.63; p=0.0344). 41 (75%) of 51 
participants in the placebo group had serious adverse 
events vs 31 (53%) of 58 in the ixmyelocel-T group 
(p=0.02) (Patel AN et al, Lancet 2016; 387:2412–2421).  
 
GAUSS-3: Among Patients With Statin Intolerance 
Due to Muscle-Related Adverse Effects, Use of 
Evolocumab Compared With Ezetimibe Resulted in a 
Significantly Greater Reduction in LDL-Cholesterol 
Levels After 24 Weeks  
Of the 491 patients who entered phase A (20 mg 
atorvastatin vs placebo) (age 60.7+10.2 years; 50% 
women; 34.6% with coronary heart disease; entry mean 
LDL-C level, 212.3 +67.9 mg/dL), muscle symptoms 
occurred in 209 (42.6%) while taking atorvastatin but not 
while taking placebo. Of these, 199 entered phase B, along 
with 19 who proceeded directly to phase B (randomization 
2:1 to subcutaneous evolocumab 420 mg monthly or 10 mg 
daily of oral ezetimibe) due to elevated creatine kinase 
(n = 218, with 73 randomized to ezetimibe and 145 to 
evolocumab; entry mean LDL-C level, 219.9 +72 mg/dL). 
For the mean of weeks 22 and 24, LDL-C with ezetimibe 
was 183 mg/dL (mean percent LDL-C change, −16.7%), 
and with evolocumab 103.6 mg/dL (mean percent change, 
−54.5%) (P < .001). LDL-C level at week 24 with 
ezetimibe was 181.5 mg/dL (mean percent change, 
−16.7%) and with evolocumab was 104.1 mg/dL (mean 
percent change, −52.8%) (P < .001). For the mean of 
weeks 22 and 24, between-group difference in LDL-C was 
−37.8%. For week 24, between-group difference in LDL-
C was −36.1%. Muscle symptoms were reported in 28.8% 
of ezetimibe-treated patients and 20.7% of evolocumab-
treated patients (log-rank P = NS). Active study drug was 
stopped for muscle symptoms in 5 of 73 ezetimibe-treated 
patients (6.8%) and 1 of 145 evolocumab-treated patients 
(0.7%) (Nissen SE et al, JAMA 2016; 315:1580-1590).   
SPRINT Trial for the Subgroup of Hypertensive 
Patients Aged >75 Years: Treating to a Systolic BP 
(SBP) Target of <120 mmHg Compared With <140 
mmHg Resulted in Significantly Lower Rates of Fatal 
and Nonfatal Major Cardiovascular Events and Death 
From Any Cause 
Among 2636 participants (mean age ~80 years; ~38% 
women; 2510 or ~95% providing complete follow-up data) 
randomized to an SBP target of <120 mmHg (intensive 
treatment group, n = 1317) or an SBP target of <140 
mmHg (standard treatment group, n = 1319), at a median 
follow-up of 3.14 years, there was a lower rate of the 
primary composite outcome (nonfatal MI, other acute 
coronary syndrome, nonfatal stroke, nonfatal acute 
decompensated heart failure, and cardiovascular death) 
(102 vs 148 events; hazard ratio - HR, 0.66) and all-cause 
mortality (73 deaths vs 107 deaths, respectively; HR, 
0.67). The overall rate of serious adverse events was not 
different between treatment groups (48.4% vs 48.3%). 
Absolute rates of hypotension were 2.4% in the intensive 
treatment group vs 1.4% in the standard treatment group 
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(HR, 1.71), 3% vs 2.4% for syncope (HR, 1.23), 4% vs 
2.7% for electrolyte abnormalities (HR, 1.51), 5.5% vs 
4.0% for acute kidney injury (HR, 1.41), and 4.9% vs 5.5% 
for injurious falls (HR, 0.91) (Williamson JD et al, JAMA 
2016;315:2673-2682).   
Quitting Smoking Abruptly vs Gradually is More 
Likely to Lead to Lasting Abstinence, Even for Those 
Who Initially Prefer to Quit by Gradual Reduction 
Among 697 adult smokers with tobacco addiction, all 
receiving behavioral support from nurses and nicotine 
replacement before and after quit day, at 4 weeks, 39.2% 
of the participants in the gradual-cessation group (reduced 
smoking gradually by 75% in the 2 weeks before quitting) 
were abstinent compared with 49% in the abrupt-cessation 
group (relative risk, 0.80). At 6 months, 15.5% of the 
participants in the gradual-cessation group were abstinent 
compared with 22% in the abrupt-cessation group (relative 
risk, 0.71). Participants who preferred gradual cessation 
were significantly less likely to be abstinent at 4 weeks 
than those who preferred abrupt cessation (38.3% vs 
52.2%; P= 0.007) (Lindson-Hawley N et al, Ann Intern 
Med 2016;164:585-592).   
Systematic Review and Meta-Analysis: Compared 
With Everolimus-Eluting Metallic Stents (EESs), 
Everolimus-Eluting Bioresorbable Vascular Scaffold 
(BVSs) do not Eliminate and Might Increase Risks for 
Stent Thrombosis and MI in Adults Having PCI  
According to 6 randomized, controlled trials and 38 
observational studies, each involving at least 40 patients 
with BVS implantation, the pooled incidence of definite or 
probable stent thrombosis after BVS implantation was 1.5 
events per 100 patient-years (PYs) (126 events during 
8508 PYs). In 6 randomized trials directly comparing 
BVSs with EESs, a non–statistically significant increased 
risk for stent thrombosis (odds ratio - OR, 2.05; P= 0.067) 
and myocardial infarction (MI) (OR, 1.38; P= 0.064) was 
observed with BVSs. The 6 observational studies that 
compared BVSs with EESs showed increased risk for stent 
thrombosis (OR, 2.32; P= 0.035) and MI (OR, 2.09; P= 
0.007) with BVSs. The relative rates of all-cause and 
cardiac death, revascularization, and target lesion failure 
were similar for BVSs and EESs (Zhang X-L et al, Ann 
Intern Med 2016;164:752-763.).   
Systematic Evidence Review: The Beneficial Effect of 
Aspirin for the Primary Prevention of CVD is Modest 
and Occurs at Doses of <100 mg/d / Older Adults Seem 
to Achieve a Greater Relative MI Benefit / Consider 
Bleeding Risk which May Vary Considerably  
According to 2 good-quality and 9 fair-quality 
randomized, controlled trials, aspirin reduced the risk for 
nonfatal myocardial infarction (MI) (relative risk - RR, 
0.78) but not nonfatal stroke; aspirin showed little or no 
benefit for all-cause or cardiovascular mortality. Benefits 
began within the first 5 years. Older adults achieved 
greater relative MI reduction, but no other effect 
modifications were found in analyzed subpopulations. In 
trials with aspirin doses of <100 mg/d, the reduction in 
nonfatal MI benefit persisted (absolute risk reduction, 0.15 
to 1.43 events per 1000 person-years) and a 14% reduction 
in nonfatal stroke benefit was noted, but no benefit was 
found for all-cause mortality (RR, 0.95) or cardiovascular 
mortality (RR, 0.97) (Guirguis-Blake JM et al, Ann Intern 
Med 2016;164:804-813).  
However, in CVD primary prevention studies, low-
dose aspirin use (≤100 mg daily or every other day) 
increased major gastrointestinal (GI) bleeding risk by 58% 
(odds ratio - OR, 1.58) and hemorrhagic stroke risk by 27% 
(OR, 1.27). Estimated excess major bleeding events were 
1.39 for GI bleeding and 0.32 for hemorrhagic stroke per 
1000 person-years of aspirin exposure using baseline 
bleeding rates from a community-based observational 
sample. Such events could be greater among older persons, 
men, and those with CVD risk factors that also increase 
bleeding risk (Whitlock EP et al, Ann Intern Med 
2016;164:826-835).  
Prolonged PR interval is Associated with Significant 
Increases in Atrial Fibrillation, Heart Failure and 
Mortality 
The results of a review and meta-analysis of 14 studies 
comprising 400,750 participants suggest an increased risk 
of mortality with prolonged PR interval risk ratio (RR) 
1.24 (5 studies). Prolonged PR interval was associated with 
significant risk of heart failure or left ventricular 
dysfunction (RR 1.39, 3 studies) and atrial fibrillation (RR 
1.45, 8 studies) but not cardiovascular mortality, coronary 
heart disease or myocardial infarction or stroke or TIA. 
Similar observations were recorded when limited to 
studies of first-degree heart block (Kwok CS et al, Heart 
2016;102:672-680).  
Atrial Fibrillation (AF) in the Setting of Myocardial 
Infarction (MI) (STEMI or NSTEMI) is Associated 
With Impaired 3-Month Outcome 
Among 155,071 hospital survivors of MI, AF was 
documented in 24,023 (15.5%) cases. The AF subtypes 
were new-onset AF with sinus rhythm at discharge (3.7%), 
new-onset AF with AF at discharge (3.9%), paroxysmal 
AF (4.9%) and chronic AF (3%). The event rate per 100 
person-years for the composite cardiovascular outcome 
(all-cause mortality, MI or ischemic stroke) was 90.9 in 
patients with any type of AF vs 45.2 in patients with sinus 
rhythm, adjusted hazard ratio (HR) 1.28. The composite 
cardiovascular outcome was similar among AF subtypes 
and between NSTEMI and STEMI. AF was associated 
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with higher risk of mortality (HR 1.59), reinfarction (HR 
1.14) and ischemic stroke (HR 2.29) (Batra G et al, Heart 
2016;102:926-933).   
XANTUS Study: Patients with Non-Valvular Atrial 
Fibrillation (AF) Receiving Rivaroxaban, Had 2.1 
Major Bleeding Events per 100 Patient-Years, 1.9 
Deaths per 100 Patient-Years, and 0.7 Stroke Events 
per 100 Patient-Years  
Among 6784 patients treated with rivaroxaban (mean 
patient age 71.5 years, range 19–99; 41% female, and 9.4% 
with documented severe or moderate renal impairment, i.e. 
creatinine clearance <50 mL/min), the mean CHADS2 was 
2.0 and CHA2DS2-VASc score 3.4; 859 (12.7%) patients 
had a CHA2DS2-VASc score of 0 or 1. The mean treatment 
duration was 329 days. Treatment-emergent major 
bleeding occurred in 128 patients (2.1 events per 100 
patient-years), 118 (1.9 events per 100 patient-years) died, 
and 43 (0.7 events per 100 patient-years) suffered a stroke 
(Camm AJ et al, Eur Heart J 2016; 37:1145-1153).  
 
EMPA-REG OUTCOME® Trial: In Patients With 
Type 2 Diabetes and High Cardiovascular (CV) Risk, 
Empagliflozin Reduced Heart Failure Hospitalization 
and Cardiovascular Death  
The initial EMPA-REG OUTCOME® trial reported 
that empagliflozin added to standard of care reduced major 
adverse CV events in patients with diabetes and high CV 
risk. In this analysis heart failure outcomes were 
investigated among 7020 patients randomized to receive 
empagliflozin 10 mg, empagliflozin 25 mg, or placebo; 
706 (10.1%) had heart failure at baseline. Heart failure 
hospitalization or CV death occurred in a lower percentage 
of patients treated with empagliflozin (5.7%) than with 
placebo (8.5%) (hazard ratio, HR: 0.66; P< 0.001); number 
needed to treat to prevent one heart failure hospitalization 
or CV death: 35 over 3 years. Empagliflozin improved 
other heart failure outcomes, including hospitalization for 
or death from heart failure (2.8 vs 4.5%; HR: 0.61; P< 
0.001) and was associated with a reduction in all-cause 
hospitalization (36.8 vs 39.6%; HR: 0.89; P = 0.003) 
(Fitchett D et al, Eur Heart J 2016;37:1526-1534).  
 
Danish Databases: All NOACs Safe and Effective 
Alternatives to Warfarin with no Significant Difference 
Between NOACs and Warfarin for Ischemic Stroke / 
Risks of Death or Bleeding Lower for Apixaban and 
Dabigatran vs Warfarin  
Among 61678 anticoagulant naïve patients with atrial 
fibrillation (AF) receiving warfarin (n=35436, 57%), 
dabigatran 150 mg (n=12701, 21%), rivaroxaban 20 mg 
(n=7192, 12%), and apixaban 5 mg (n=6349, 10%), 
NOACs were not significantly different from warfarin 
with regards to ischemic stroke. At 1 year, rivaroxaban was 
associated with lower annual rates of ischemic stroke or 
systemic embolism (3% vs 3.3%, respectively) compared 
with warfarin: hazard ratio – HR 0.83. HRs for dabigatran 
and apixaban (2.8% and 4.9% annually, respectively) were 
non-significant compared with warfarin. The annual risk 
of death was significantly lower with apixaban (5.2%) and 
dabigatran (2.7%) (HR 0.65 and 0.63, respectively) 
compared with warfarin (8.5%), but not with rivaroxaban 
(7.7%). For the combined endpoint of any bleeding, annual 
rates for apixaban (3.3%) and dabigatran (2.4%) were 
significantly lower than for warfarin (5%) (HR 0.62). 
Warfarin and rivaroxaban had comparable annual bleeding 
rates (5.3%) (Larsen TB et al, BMJ 2016;353:i3189).  
 
ORBIT-AF registry: Patients With a Family History of 
AF Developed AF at a Younger Age, had Less 
Comorbidity, and were more Symptomatic. Once AF 
Developed, No Significantly Increased Risks  
Among 9,999 US patients with AF, 1,481 (14.8%) had 
a family history of AF. Relative to those without, those 
with a family history of AF developed AF 5 years earlier 
(median age 65 vs 70 years, P<0.01), with less comorbi-
dity, and had more severe AF-related symptoms. No 
differences were found between the 2 groups in the risk of 
AF progression, stroke, non–central nervous system 
embolism, or TIA, all-cause hospitalization, and all-cause 
death (Gundlund A et al, Am Heart J 206;175:28–35).  
 
CHARGE & FORCe: Consumption of Omega 3s 
Linked to Lower Risk of Fatal Coronary Heart Disease 
(CHD) 
Analysis of 19 cohort studies evaluating biomarkers of 
seafood-derived eicosapentaenoic acid (EPA), docosa-
pentaenoic acid (DPA), and docosahexaenoic acid (DHA) 
and plant-derived α-linolenic acid (ALA) for incident 
CHD, in 45 637 individuals (median age at baseline 59 
years; ~63% male) documented 7973 total CHD, 2781 
fatal CHD, and 7157 nonfatal MI events. The ω-3 
biomarkers ALA, DPA, and DHA were associated with a 
lower risk of fatal CHD, with relative risks (RRs) of 0.91 
for ALA, 0.90 for DPA, and 0.90 for DHA. Although DPA 
was associated with a lower risk of total CHD (RR, 0.94), 
ALA (RR, 1.00), EPA (RR, 0.94), and DHA (RR, 0.95) 
were not. Significant associations with nonfatal MI were 
not evident. Associations appeared generally stronger in 
phospholipids and total plasma (Del Gobbo LC et al, 
dx.doi.org/10.1001/jamainternmed.2016.2925).  
 
Influenza Infection is Associated with AF (18% 
Increased Risk), which is Reduced with Vaccination 
Among 11,374 patients with newly diagnosed AF, 
those with compared with those without influenza 
infection or vaccination (n = 38,353), patients with 
influenza infection without vaccination (n = 1369) were 
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associated with a significantly higher risk of AF with an 
odds ratio of 1.182 (P = 0.032) after adjustment for 
baseline differences. The risk of AF was lower in patients 
receiving influenza vaccination without influenza 
infection (n = 16,452) with an odds ratio - OR of 0.881 (P 
< 0.001). In patients who received vaccination and 
experienced influenza infection (n = 696), the risk of AF 
was similar to that in the reference group (OR 1.136; P = 
NS) (Chang T-Y et al, Heart Rhythm 2016; 13:1189–94).  
 
ARISTOTLE trial: A History of Bleeding is Associated 
With Several Risk Factors for Stroke and Higher Risk 
of Major—but not Intracranial—Bleeding, During 
Anticoagulation / The Beneficial Effects of Apixaban 
over Warfarin for Stroke, Hemorrhagic Stroke, Death, 
or Major Bleeding Remain Consistent Regardless of 
History of Bleeding  
Among 18,140 patients receiving apixaban or warfarin, 
a bleeding history was reported at baseline in 3,033 
patients (16.7%), who more often were male, with a history 
of prior stroke/TIA/systemic embolism and diabetes; 
higher CHADS2 scores, age, and body weight; and lower 
creatinine clearance and mean systolic blood pressure. 
Major (but not intracranial) bleeding occurred more 
frequently in patients with vs without a history of bleeding 
(hazard ratio 1.35). There were no significant interactions 
between bleeding history and treatment for 
stroke/embolism, hemorrhagic stroke, death, or major 
bleeding, with fewer outcomes with apixaban vs warfarin 
for all of the outcomes independent of a bleeding history 
(De Katerina R et al, Am Heart J 2016; 175:175–183).  
 
Meta-Analysis: Left Atrial Appendage Occlusion (LAAO) is 
not Superior over NOACs for Stroke Prevention, but 
consistently has Lower Thromboembolic & Bleeding events 
Per 6 RCTs and 27 observational studies LAAO was less 
effective than NOACs for stroke prevention (odds ratio 0.86), but 
had a lower rate of hemorrhagic events during follow-up. 
However, a meta-proportion analysis of observational studies 
revealed that LAAO was associated with a lower rate of both 
thromboembolic events (1.8 vs 2.4 events per 100 patient-years) 
and major bleeding events during follow-up (2.2 vs 2.5 events per 
100 patient-years) as compared with NOACs. With prolonged 
follow-up duration after LAAO implantation, the rate of 
thromboembolic events decreased (Li X et al, Heart Rhythm 
2016;13:1203–1214).  
 
Drug-Induced Brugada Synrome from Noncardiac 
Drugs Occurs Predominantly in Adult Males, Usually 
Late after the Onset of Therapy  
A total of 74 cases of drug-induced Brugada syndrome 
from 27 noncardiac medications were identified: 77% 
were male, and drug toxicity was involved in 46%. It 
generally occurred weeks after the initiation of therapy. 
Mortality was 13%. All cases had a type I Brugada pattern 
during drug therapy. Nevertheless, their ECG in the 
absence of drugs was more frequently abnormal than the 
ECG of controls (56% vs 33%, P = o.04). Among the 
cases, 36 (49%) were induced by psychotropic drugs, 20 
(27%) were induced by analgesic–anesthetic drugs, and 18 
(24%) were induced by other noncardiac drugs. The most 
frequently reported agent was intravenous propofol (20% 
of cases). The most frequently reported oral agents were 
lithium (20%) and amitriptyline (16%). The complete list 
of drugs can be found at www.brugadadrugs.org 
(Konigstein M et al, Heart Rhythm 2016; 13:1083–1087).  
 
Important Review and Other Articles  
 
 2015 ACC/AHA/HRS Guideline for the management of 
supraventricular tachycardia (Page RL et al, J Am Coll 
Cardiol 2016;67:1575-1623), Risk stratification for 
arrhythmic events in patients with asymptomatic pre-
excitation (Al-Khatib SM et al, J Am Coll Cardiol 
2016;67:1624-1638), Drug-induced QT prolongation and 
torsade de pointes (Schwartz PJ, Woosley RL, J Am Coll 
Cardiol 2016;67:1639-1650), Kawasaki disease 
(Newburger JW et al, J Am Coll Cardiol 2016;67:1738-
1749), Treatment of venous thromboembolism with new 
anticoagulants (Becattini C & Agnelli G, J Am Coll 
Cardiol 2016;67:1941-1955), Constrictive pericarditis vs 
restrictive cardiomyopathy (Garcia MJ, J Am Coll Cardiol 
2016;67:2061-2076), Asymptomatic severe aortic stenosis 
(Généreux P et al, J Am Coll Cardiol 2016;67:2263-2288), 
Sinus node and atrial arrhythmias (John RM & Kumar S, 
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